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Background: Using immunohistochemistry (IHC) to select cases for mismatch repair (MMR) genetic testing, we
failed to identify a large kindred with the deleterious PMS2 mutation c.989-1G > T. The purpose of the study was to
examine the sensitivity of IHC and microsatellite instability-analysis (MSI) to identify carriers of the mutation, and to
estimate its penetrance and expressions.
Methods: All carriers and obligate carriers of the mutation were identified. All cancer diagnoses were confirmed.
IHC and MSI-analysis were performed on available tumours. Penetrances of cancers included in the Amsterdam and
the Bethesda Criteria, for MSI-high tumours and MSI-high and low tumours were calculated by the Kaplan-Meier
algorithm.
Results: Probability for co-segregation of the mutation and cancers by chance was 0.000004. Fifty-six carriers or
obligate carriers were identified. There was normal staining for PMS2 in 15/18 (83.3%) of tumours included in the
AMS1/AMS2/Bethesda criteria. MSI-analysis showed that 15/21 (71.4%) of tumours were MSI-high and 4/21 (19.0%)
were MSI-low. Penetrance at 70 years was 30.6% for AMS1 cancers (colorectal cancers), 42.8% for AMS2 cancers,
47.2% for Bethesda cancers, 55.6% for MSI-high and MSI-low cancers and 52.2% for MSI-high cancers.
Conclusions: The mutation met class 5 criteria for pathogenicity. IHC was insensitive in detecting tumours caused by
the mutation. Penetrance of cancers that displayed MSI was 56% at 70 years. Besides colorectal cancers, the most
frequent expressions were carcinoma of the endometrium and breast in females and stomach and prostate in males.
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Lynch Syndrome (LS) is a multi organ cancer syndrome
caused by germline mutations in the four MMR genes
MLH1, MSH2, MSH6 and PMS2. The tumour spectrum
includes colorectal- and endometrial cancer as the pre-
dominant cancers, and carcinoma of the upper uro-
epithelial tract, ovary, hepatobiliary tract, brain, stomach
and prostate with lower frequency.* Correspondence: eli.marie.grindedal@ous-hf.no
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unless otherwise stated.The PMS2 gene was the last of the four MMR genes
to be identified as a cause of LS [1]. It has been sug-
gested that PMS2 mutations may be associated with a
later age of onset of cancer than MLH1 and MSH2
mutations [1]. However, reports are few and the exact
penetrance and expression of mutations in PMS2 is con-
sidered unknown [2].
Tumours caused by a pathogenic germline mutation in
one of the MMR genes have specific characteristics.
Firstly, they display microsatellite instability (MSI).
Microsatellites are DNA-sequences found throughout
the genome where one or units of two or more nucleo-
tides are repeated a certain number of times. A changeral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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deletion of repeating units during DNA replication and a
failure of the MMR complex to correct these errors is
called MSI. Usually, a panel of six markers is used to in-
vestigate whether a tumour displays MSI or not. If there is
instability in two or more markers the tumour is con-
sidered MSI-high. If only one marker shows instability,
the tumour is considered MSI-low. Secondly, tumours
caused by pathogenic mutations in one of the MMR genes
lack expression of the gene product from the mutated
gene [3,4]. The presence or absence of gene products from
the MMR genes is investigated by immunohistochemistry
(IHC) on formaline-fixated tumour specimens. Genetic
testing of tumour tissue has several advantages. It is a
cheap method that can be used to select patients for more
extensive testing of blood by Sanger sequencing and
MLPA and one may test deceased relatives.
In general, the sensitivity of MSI and IHC to detect car-
riers of MMR-mutations is considered to be high [5,6].
However, differences between the genes have been de-
scribed. It has recently been reported that 95% of cancers
occurring in carriers of mutations in MLH1 or MSH2 lack
staining of gene product from the mutated gene, com-
pared to 71% of cancers in MSH6 mutation carriers [7]. In
addition, whereas 90% of tumours caused by MLH1 and
MSH2 mutations display MSI [8], tumours caused by
MSH6 mutations show lower levels of MSI and may be
classified as MSS or MSI-low [6]. The clinical sensitivity
of IHC and MSI to detect carriers of PMS2-mutations is
not known [9].
It has been demonstrated that PMS2-mutation carriers
develop cancers that show selective loss of PMS2 by
IHC [1,10,11] and that this is advocated to be followed
by PMS2 mutation testing in blood [1].
In 1999 a large family fulfilling the revised Amsterdam
Criteria was referred to the Section for Inherited Cancer
at the Oslo University Hospital. IHC was performed on
tumours from several of the affected relatives during the
following years, showing normal staining of all MMR-
genes. Despite the normal staining in tumour tissue, a
blood sample from a woman with a prospectively de-
tected endometrial cancer was tested for mutations in all
the MMR genes when such testing became available. A
pathogenic splice variant PMS2 c.989-1G > T was de-
tected. The variant had previously been reported [12]. It
is now found to be a local frequent mutation in Mid-
Norway (unpublished result), and it has also been de-
tected in families living in the south of Norway.
The identification of the mutation in the large family
had been delayed several years due to the normal IHC-
results in mutation carriers. The aim of the study was to
examine the sensitivity of IHC and MSI to identify car-
riers in cancer cases, and the penetrance and expressions
of the mutation.Methods
All carriers and obligate carriers of the mutation were
identified in the databases at the Section for Inherited
Cancer at Oslo University Hospital and at the Department
of Medical Genetics at St. Olav’s Hospital in Trondheim.
All cancer diagnoses were confirmed from medical files or
from The Cancer Registry of Norway.
IHC and MSI-analysis were performed on paraffin
blocks from all available tumours. The analyses were
performed as described in Sjursen et al. [12]. The PMS2
antibody was monoclonal, clone A16-4, from BD Phar-
mingen (CA, USA). BD Pharmingen reported to have
used recombinant human PMS2 C-terminal half (codon
431–862) as immunogen in antibody development. DNA
mutation analyses for the PMS2 variant c.989-1G > T
were performed by Sanger sequencing and the PCR
primers and conditions are also described in Sjursen
et al. 2009 [12].
As previously described, demonstrated and obligate
mutation carriers were included in segregation analysis
to determine probability for co-segregation of the muta-
tion and disease by chance [13].
The Kaplan-Meier Algorithm was used to calculate
time from birth to any cancer in demonstrated or obli-
gate carriers. Also, penetrances were calculated sepa-
rately for MSI-high tumours and for tumours that were
MSI-high or MSI-low. In the latter analyses cancers with
inconclusive results of MSI or no MSI performed were
excluded.
No named data was exported from the medical files.
All patients alive had at least one genetic counseling ses-
sion, and all genetic testing included written informed
consent and were conducted according to national legis-
lation. The study was approved by the Ethical review
board (ref S02030) and the Norwegian Data Inspectorate
(ref 2001/2988-2). The present report is one in a series
to meet the request from The Norwegian Parliament to
report the results of our activities.
Results
Forty-eight carriers and 8 obligate carriers were identi-
fied, giving a total of 56 individuals that were included
in the study, 33 women and 23 men. 19/56 (33.9%) were
affected with at least one cancer included in the AMS1/
AMS2/Bethesda criteria, and 22/56 (39.3%) were af-
fected with any cancer, 13 women and 9 men. Segrega-
tion analysis showed 19 informative meioses, giving a
probability of co-segregation by chance of (1/2)18 corre-
sponding with a probability of pathogenicity of 0.999996.
The most frequently observed cancer both in men and
women was colorectal cancer, occurring in 12/22 (54.5%)
of the affected with a mean age of 46.9 years (range
26–75). In women colorectal-, endometrial- and breast
cancer occurred in 6/13 (46.2%), 5/13 (38.5%) and 3/13
Table 1 Expression of cancers in carriers of PMS2
c.989-1G > T
Cancer All (n = 22) Women (n = 13) Men (n = 9)
Colorectum 12 (54.5%) 6 (46.2%) 6 (66.7%)
Stomach 3 (13.6%) - 3 (33.3%)
Kidney 1 (4.5%) 1 (7.7%) -
Malignant melanoma 1 (4.5%) 1 (7.7%) -
Sarcoma 1 (4.5%) 1 (7.7%) -
Endometrium - 5 (38.5%) -
Ovary - 1 (7.7%) -
Breast - 3 (23.1%) -
Prostate - - 2 (22.2%)
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tate cancer, occurred in 6/9 (66.7%), 3/9 (33.3%) and 2/9
(22.2%) respectively (Table 1).
In sum, IHC was performed on 24 tumours, and 21/24
(87.5%) showed expression of PMS2. Of tumours in-
cluded in AMS1/AMS2/Bethesda criteria 15/18 (83.3%)
showed normal staining for PMS2 with IHC. Three
breast cancers, one sarcoma, one prostate cancer and
one renal cancer, all showed normal IHC for PMS2
(Figure 1).
MSI analysis was performed on altogether 23 tumours
in mutation carriers, and 21 gave conclusive results.
Nineteen out of twenty-one (90.5%) of the tumours were
MSI. Fifteen out of twenty-one (71.4%) were MSI-high
and 4/21 (19.0%) of the tumours were MSI-low. The tu-
mours that were MSI-low were one endometrial cancer,
one breast cancer, one prostate cancer and one gastric
cancer. Six of the tumours available for MSI-analyses
were not included in the AMSI/AMSII/Bethesda criteria;
three breast cancers, one renal cancer, one prostate can-
cer and one sarcoma. All but one of the breast cancers
and the renal cancer were MSI. The sarcoma and one
breast cancer were MSI-high. The prostate cancer and
the other breast cancer were MSI-low (Table 2).Figure 1 Endometrial cancers in carriers of PMS2 c.989-1G > T with an
of the endometrium. Immunhistochemical reaction shows expression (left) or
tumour sample provide positive control. Both tumours displayed MSI.The three tumours that showed no staining of PMS2
by IHC were two colorectal cancers and one endometrial
cancer. MSI-analysis was performed on one of the colo-
rectal cancers and on the endometrial cancer, and both
tumours were MSI-high.
Penetrance at 30, 50 and 70 years was 1.8%, 15.7% and
30.6% for AMS1 cancers (colorectal cancers), 1.8%, 18%
and 42.8% for AMS2 cancers, 3.6%, 20.9% and 47.2% for
Bethesda cancers and 3.6%, 22.8%, and 60.5% for any can-
cer. Penetrance of cancers that were either MSI-high or
MSI-low at 30, 50 and 70 years was 3.9%, 17.2% and
55.6%. Penetrance of cancers that were MSI-high at 30, 50
and 70 years was 3.9%, 17.2% and 52.2% (Figures 2, 3, 4, 5,
6 and 7).
Discussion
The splice mutation PMS2 c.989-1G > T met the InSiGHT
criteria class 5 for pathogenicity [14]: mRNA analysis
showed that it caused two abnormal transcripts, it co-
segregates with disease, more than 2 tumours were
MSI-high and has a population frequency <1%. However,
whereas 90% of tumours in mutation carriers were MSI-
high or MSI-low, only 12.5% of tumours showed abnormal
staining of PMS2 by IHC. Penetrance of MSI cancers at
age 70 was 56%.
Several studies have demonstrated that PMS2 mutation
carriers can be identified among patients with MSI-high
tumours and/or loss of PMS2 in tumour tissue. Gill and
colleagues found that 72% of MSI-high tumours, showing
normal staining for MLH1, MSH2 and MSH6 showed
selective loss of PMS2 [11]. In a series of 1048 unselected
consecutive cases of CRC selective loss of PMS2 was
observed in 1.5% of tumours, which was similar to the fre-
quency of loss of MSH2. Several mutations in the PMS2
gene were identified among the patients with PMS2-
deficient tumours [10]. Accordingly, tumour testing by
IHC and MSI is used as a screening tool to select patients
for genetic testing for mutations in PMS2. However, the
clinical sensitivity of IHC and MSI to detect PMS2 muta-
tion carriers is not known. In our series, IHC alone wouldd without expression of PMS2. IHC analysis of two adenocarcinomas
no expression (right) of PMS2. Magnification × 20. Lymphocytes in the
Table 2 IHC/MSI profile according to type of cancer
Tumour type IHC performed PMS2 expressed Loss of PMS2 expression MSI performed MSS MSI high MSI low
Colorectal 11 9 2 9 9
Gastric 2 2 0 2 1 1
Endometrial 4 3 1 3 2 1
Prostate 1 1 0 1 1
Ovarian 1 1 0 1 1
Breast 3 3 0 3 1 1 1
Sarcoma 1 1 0 1 1
Renal 1 1 0 1 1
Sum 24 21 (87.5%) 3 21 2 15 (71.4%) 4 (19.0%)
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riers. We have previously reported a homozygous carrier
of PMS2 c.989-1G > T with Turcot syndrome [12]. cDNA-
analysis demonstrated that the splice site mutation leads
to two abnormal transcripts, one missing exon 10 and the
other missing the first 27 nucleotides of exon 10. The
latter may be caused by splicing with a cryptic acceptor
site. The first part of exon 10 is highly conserved and it
contains the catalytically important 340Lys residue for
ATP hydrolysis [15]. It also contains the end of the func-
tional domains DNA mismatch repair protein N-terminal
and C-terminal (IPR014763 and IPR013507 respectively).
None of the transcripts led to frame shift, and this may
prevent them from being degraded by nonsense mediated
mRNA decay [16,17]. The normal IHC may therefore re-
flect that the transcripts are translated into non-functional
proteins being transferred to the nucleus where they bindFigure 2 Penetrance of cancers included in the Amsterdam
clinical criteria.to the epitope of the PMS2 antibody. This hypothesis is
supported by the fact that the antibody binds to some-
where between codon 431–862 which is downstream to
the deletions in the two gene products of the mutation.
Further the PMS2 exon 10 deletions in the transcripts do
neither affect the MLH1 binding domain (codon 675–850
[18]) nor the nuclear localisation signal (codon 625–632
[19]). Thus, the low sensitivity of IHC to detect tumours
caused by the PMS2 splice mutation is in keeping with a
non-functional protein located at the right place in the cell
detectable by IHC. Interestingly, a recent study on dis-
crepancies between IHC and MSI results reported that of
646 consecutive tumours investigated, as many as 11.8%
of the tumours that were MSI high showed normal ex-
pression of all MMR genes. Eight of these 12 tumours
were from patients that had a first degree relative with a
LS associated cancer. It is not known how many of theFigure 3 Penetrance of cancers included in the revised
Amsterdam clinical criteria.
Figure 4 Penetrance of cancers included in the Bethesda
clinical criteria.
Figure 6 Penetrance of cancers that were either MSI-high
or MSI-low.
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tation [20].
We observed that all colorectal-, gastric, endometrial-,
prostate- and ovarian cancers and 2/3 of breast cancers
occurring in carriers of the PMS2 mutation displayed
MSI. In addition, the sarcoma was also MSI high. Of the
tumours investigated, only the renal cancer and one
breast cancer were MSS. MSI analysis is considered a
sensitive method to identify MMR mutation carriers,Figure 5 Penetrance of any cancer.and one could hypothesize that all cancers caused by
a pathogenic germline MMR mutation would display
MSI. However, it is well known that tumours caused by
MSH6 mutations may show lower levels of MSI and
may be classified as MSS or MSI-low [6]. The fraction
of tumours that display MSI may also be different for
different cancer types. Gylling and colleagues reported
that 100% of gastric cancers and more than 90% of colo-
rectal cancers in MMR mutation carriers (>90% wereFigure 7 Penetrance of cancers that were MSI-high.
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to 63% of endometrial cancers and 25% of renal cancers
[21]. Similarly, it has been reported that 60% and 45% of
breast cancers occurring in MSH2 and MLH1 mutation
carriers respectively were MSI high, whereas all breast
cancers in MSH6 mutation carriers were MSS [22]. Our
observations indicate that MSI analysis may be used to
identify PMS2 mutation carriers among patients with
extra-colonic as well as colonic cancers. However, larger
numbers are required to assess whether the fraction of
colonic and extra-colonic tumours that display MSI are
different from the other MMR genes.
A recent study has demonstrated that IHC has a low
sensitivity in identifying pathogenic MSH6-mutations, as
almost 24% of adenocarcinomas in carriers of pathogenic
MSH6 mutations showed normal staining of this gene
[23]. The explanation for this finding remains unknown.
We observed that in carriers of PMS2 c.989-1G > T 83%
of cancers included in the AMS1/AMS2/Bethesda clinical
criteria had normal expression of PMS2. Whether the sen-
sitivity of IHC to identify carriers of PMS2-mutations is
similar to MSH6 or to the high sensitivity reported for tu-
mours caused by MLH1- or MSH2-mutations cannot be
addressed in the present study where carriers of only one
mutation were included, but needs further clarification.
The exact penetrance and expression associated with
mutations in PMS2 is not known [2]. Previous reports
have referred to the gene as giving an attenuated form of
Lynch Syndrome, a lower risk of CRC and a later age of
onset than what has been described for MLH1 and MSH2
[1]. Several studies have also demonstrated that the major-
ity of families do not fulfill the clinical criteria for LS
[1,10,11,24,25]. We observed that penetrance at 70 years
for CRC was 30% and 56% for MSI cancers. This may be
in keeping with previous studies, and may indicate that
risk of CRC is lower than what has been reported for car-
riers of mutations in MLH1 and MSH2 [26]. We also
observed that after colorectal cancer, endometrial- and
breast cancer were the most commonly observed cancers
in women, and gastric- and prostate cancers in men.
Conclusions
The class 5 pathogenic splice mutation PMS2 c.989-1G >T
had a penetrance for MSI cancers of 56% at 70 years of
age. Colorectal cancer was most frequently seen, while ex-
pressions included breast-, gastric- and prostate cancers as
well. IHC detected only 12.5% of the tumours caused by
the mutation. Our observations illustrate the importance
of performing both IHC and MSI analysis when selecting
patients for MMR genetic testing.
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